Dr. Lechleiter Talks Biopharma Innovation in China

Dr. Lechleiter Talks Biopharma Innovation in China

11.28.12 | By

Few things exemplify the promise, challenges and opportunities confronting the global biopharmaceutical research sector as do efforts to foster biopharma innovation in China.

Dr. John C. Lechleiter, Eli Lilly CEO and PhRMA Chairman, is in China this week as part of PhRMA's Second Annual China Days. As he travels the country, Dr. Lechleiter is highlighting the growing importance of biopharmaceutical innovation to China and its patients, as well as what China can do to stimulate continued industry growth.

Dr. Lechleiter spent Monday in Chengdu, a city of more than 10 million people. While there, he met with city officials, hospital staff, and patients to discuss the importance of delivering innovative healthcare to patients there and throughout China.

During his trip, Dr. Lechleiter will also be emphasizing how collaboration with academics, government and local industry is critical to the development of safe and innovative new medicines - discussions and exchanges that will not only benefit Chinese patients, but also patients around the world.

Check back here at the Catalyst for further updates on Dr. Lechleiter's trip and you can also follow his progress here.

More On PhRMA — powered by PhRMApedia


Cost in Context